Evidence map›Paper›PMID 39733430›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2024

Analysis of the Effectiveness and Coverage of Breast, Cervical, and Colorectal Cancer Screening Programs in Kazakhstan for the Period 2021-2023: Regional Disparities and Coverage Dynamics.

Alfiya Shamsutdinova, Gulnara Kulkayeva, Zhadyra Karashutova, Baimakhan Tanabayev, Shynar Tanabayeva, Anel Ibrayeva, Ildar Fakhradiyev

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alfiya ShamsutdinovaS.D.Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Gulnara KulkayevaSalidat Kairbekova National Research Center for Health Development, Astana, Kazakhstan.
Zhadyra KarashutovaSalidat Kairbekova National Research Center for Health Development, Astana, Kazakhstan.
Baimakhan TanabayevSouth- Kazakhstan Medical Academy, Shymkent, Kazakhstan.
Shynar TanabayevaS.D.Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Anel IbrayevaS.D.Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Ildar FakhradiyevS.D.Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.ORCID https://orcid.org/00

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer screening is a crucial component in the fight to reduce cancer incidence and mortality. Currently, the WHO recommends highly effective cancer screening programs, including screening for cervical cancer (CC), breast cancer (BC), and colorectal cancer (CRC). Despite the implementation of a cancer screening program since 2014, an evaluation of the effectiveness of BC, CC, and CRC screening in the Kazakhstan has not yet been conducted. Study aimed to assess the effectiveness and coverage of BC, CC, and CRC screening in the Republic of Kazakhstan during the period from 2021 to 2023.

methodsData for the retrospective analysis were extracted from the "Healthcare Statistics" database. Data on participants eligible for screening (n=8,167,184) for BC, CC, and CRC were included in the analysis.

resultsIn 2023, there was a noticeable decrease in the number of detected cases of CC (1.7) compared to previous years. The detection rates for BC (14) and CRC (around 1) per 100,000 population in 2023 remained almost at the same level as in previous years. The detection rate for BC was 0.74% in 2021, followed by a decline to 0.59% in 2022. In 2023, there was an increase to 1.69%. As for CC, the detection rate was 0.70% in 2021, it increased to 0.77% in 2022, but then decreased again to 0.53% in 2023. CRC shows a steady decline in detection rates. In 2021, the detection rate was 4.23%, then it dropped to 3.64% in 2022, and continued to decrease to 3.28% in 2023.

conclusionsThe data for 2021-2023 underscore the necessity for continuous monitoring, analysis, and adaptation of screening strategies, taking into account regional peculiarities and new challenges, such as the pandemic. Ensuring high screening coverage for BC, CC, and CRC is a key factor for the early detection and effective treatment of these diseases.

Indexed as

Breast NeoplasmsColorectal NeoplasmsEarly Detection of CancerUterine Cervical NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansIncidenceKazakhstanMaleMass ScreeningMiddle AgedPrognosisRetrospective StudiesEfficiencynational cancer screeningNeoplasmsscreening coverage

Identifiers

PMID39733430
PMCPMC12008358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.